Breaking News Instant updates and real-time market news.

ACOR

Acorda Therapeutics

$23.55

2.5 (11.88%)

07:07
01/08/18
01/08
07:07
01/08/18
07:07

Acorda Therapeutics sees FY18 Ampyra net revenue $330M-$350M

AMPYRA net revenue is expected to be $330-$350 million. The Company expects to maintain exclusivity of AMPYRA at least through July 30, 2018; this guidance is subject to change based on the appellate court's decision. R&D expenses for the full year 2018 are expected to be $100-$110 million and include manufacturing expenses associated with INBRIJA. SG&A expenses for the full year 2018 are expected to be $170-$180 million. Year-end cash balance for 2018 is projected to be over $300 million.

  • 08

    Jan

  • 08

    Jan

ACOR Acorda Therapeutics
$23.55

2.5 (11.88%)

11/16/17
JANY
11/16/17
NO CHANGE
Target $17
JANY
Neutral
Acorda Therapeutics price target cut to $17 from $26 at Janney Capital
Janney Capital analyst Ken Trbovich lowered Acorda Therapeutics' price target to $17 from $26 following the company's announcement regarding adverse events related to Tozadenant. The analyst removed Tozadenant from his model and maintains a Neutral rating on shares.
11/20/17
LEER
11/20/17
NO CHANGE
LEER
Market Perform
Acorda discontinuation of Tozadenant a 'good strategic step,' says Leerink
Leerink analyst Paul Matteis points out that Acorda Therapeutics announced the discontinuation of Tozadenant development in Parkinson's disease in light of a recent safety update last week, noting a significant imbalance in agranulocytosis, sepsis and mortality on drug versus placebo. The analyst notes that he had removed tozadenant from his valuation based on his view that even if the drug had succeeded, these safety issues and related monitoring requirements would be too great of a cost in the context of a moderate symptomatic benefit. The discontinuation of Tozadenant should conserve some cash, he contends, adding that the company's decision is smart as the strategic focus fully shifts to CVT-301, also for Parkinson's Disease. Matteis reiterates a Market Perform rating on the shares.
11/21/17
JANY
11/21/17
NO CHANGE
Target $17
JANY
Neutral
Acorda could be worth $17-$27 in takeover, says Janney Capital
After Acorda Therapeutics announced that it is discontinuing development of tozadenant, an investigational treatment for Parkinson's disease, Janney Capital analyst Ken Trbovich said he believes a sale process appears necessary to protect shareholders from downside that he sees if Acorda remains independent. While the stock may only be worth $10-$11 if Acorda stays independent, it could be worth $17-$27 in a takeout scenario, estimated Trbovich, who maintains a Neutral rating and $17 fair value estimate on Acorda shares.
11/28/17
PIPR
11/28/17
INITIATION
Target $22
PIPR
Neutral
Acorda Therapeutics assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Charles Duncan assumed coverage of Acorda Therapeutics with a Neutral rating and $22 price target. The analyst believes Inbrija could be a best-in-class acute treatment with $800M in peak U.S. sales. He's looking for clinical and regulatory progress "which re-establishes conviction in Acorda's execution."

TODAY'S FREE FLY STORIES

VAR

Varian Medical

$118.75

0.3 (0.25%)

06:03
05/22/18
05/22
06:03
05/22/18
06:03
Hot Stocks
Varian notifies Sirtex it will not submit counterproposal to competing bid »

Varian announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSCO

Tractor Supply

$73.63

0.79 (1.08%)

06:03
05/22/18
05/22
06:03
05/22/18
06:03
Recommendations
Tractor Supply analyst commentary  »

Tractor Supply price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

PLAB

Photronics

$8.45

0.5 (6.29%)

06:02
05/22/18
05/22
06:02
05/22/18
06:02
Earnings
Photronics sees Q3 EPS 12c-18c, consensus 9c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

PPBI

Pacific Premier

$42.30

0.35 (0.83%)

06:01
05/22/18
05/22
06:01
05/22/18
06:01
Hot Stocks
Pacific Premier receives stockholder approval for issuance of shares »

Pacific Premier Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

TOL

Toll Brothers

$43.60

0.43 (1.00%)

06:01
05/22/18
05/22
06:01
05/22/18
06:01
Hot Stocks
Toll Brothers sees Q3 deliveries between 2,100 and 2,200 units »

Toll Brothers expects FY…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

PLAB

Photronics

$8.45

0.5 (6.29%)

06:01
05/22/18
05/22
06:01
05/22/18
06:01
Earnings
Photronics reports Q2 EPS 15c, consensus 7c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

TOL

Toll Brothers

$43.60

0.43 (1.00%)

06:00
05/22/18
05/22
06:00
05/22/18
06:00
Earnings
Toll Brothers sees FY18 revenue $6.64B-$7.31B, consensus $6.97B »

Based on FY 2018's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

GRUB

GrubHub

$103.64

-0.145 (-0.14%)

05:58
05/22/18
05/22
05:58
05/22/18
05:58
Recommendations
GrubHub analyst commentary  »

GrubHub price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 12

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

05:58
05/22/18
05/22
05:58
05/22/18
05:58
Periodicals
U.S., China reach broad outline on deal to settle ZTE controversy, WSJ reports »

The U.S. and China have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

HURN

Huron

$38.30

0.65 (1.73%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Conference/Events
Huron management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

TOL

Toll Brothers

$43.60

0.43 (1.00%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Earnings
Toll Brothers reports Q2 EPS 72c, consensus 76c »

Reports Q2 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

WWE

WWE

$57.86

6.37 (12.37%)

05:56
05/22/18
05/22
05:56
05/22/18
05:56
Conference/Events
WWE management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WD

Walker & Dunlop

$56.10

1.07 (1.94%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
Walker & Dunlop management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 31

    May

BUD

AB InBev

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Upgrade
AB InBev rating change  »

AB InBev upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$201.75

2.8 (1.41%)

, BAYRY

Bayer

$0.00

(0.00%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

MMM

3M

$201.75

2.8 (1.41%)

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$228.74

3.73 (1.66%)

BIIB

Biogen

$277.69

-2.66 (-0.95%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

TEVA

Teva

$21.09

-0.14 (-0.66%)

UTHR

United Therapeutics

$104.12

-2.2 (-2.07%)

VCYT

Veracyte

$6.45

(0.00%)

VRTX

Vertex

$156.15

-1.09 (-0.69%)

NBRV

Nabriva Therapeutics

$4.54

-0.89 (-16.39%)

GILD

Gilead

$67.63

-0.38 (-0.56%)

GSK

GlaxoSmithKline

$40.05

0.005 (0.01%)

HRC

Hill-Rom

$90.70

0.12 (0.13%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

CELG

Celgene

$74.69

-3.7 (-4.72%)

JAZZ

Jazz Pharmaceuticals

$166.01

-1.59 (-0.95%)

ISRG

Intuitive Surgical

$463.18

4.3 (0.94%)

INSM

Insmed

$26.34

-2.16 (-7.58%)

REGN

Regeneron

$296.58

-5.29 (-1.75%)

OCX

OncoCyte

$2.50

-0.05 (-1.96%)

FGEN

FibroGen

$52.55

1.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 20

    Oct

  • 20

    Dec

CCJ

Cameco

$11.38

0.015 (0.13%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Cameco rating change  »

Cameco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$38.17

0.77 (2.06%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Teradyne management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 30

    May

RTN

Raytheon

$213.95

2.88 (1.36%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Raytheon rating change  »

Raytheon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$11.96

-0.41 (-3.31%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Syros Pharmaceuticals management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SPSC

SPS Commerce

$71.88

0.11 (0.15%)

05:53
05/22/18
05/22
05:53
05/22/18
05:53
Conference/Events
SPS Commerce management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 29

    May

  • 12

    Jun

RDCM

Radcom

$19.65

0.25 (1.29%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Conference/Events
Radcom management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 24

    May

  • 29

    May

INFO

IHS Markit

$51.60

0.13 (0.25%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Upgrade
IHS Markit rating change  »

IHS Markit upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTM

Quantum

$3.62

-0.06 (-1.63%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.